NCT04765709 2025-12-16
BRIDGE
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
Clinical Trials
45 trialsNCT05583110 2025-12-10
TrasTUCAN
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT02974426 2024-06-12
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 3 Terminated
NCT02585388 2023-09-06
CHEOPS
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT03891173 2022-08-12
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
Helix BioPharma Corporation
Phase 2 Terminated
NCT02644252 2021-05-03
Toco-Pulm
Vejle Hospital
Phase 3 Terminated
NCT02730091 2021-02-01
VICTORIANE
Centre Hospitalier Universitaire de Besancon
Phase 3 Terminated
NCT00054197 2020-10-05
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT00075673 2020-07-27
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT02985203 2020-03-12
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT02658084 2019-04-17
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
University of Miami
Phase 1/2 Terminated
NCT00130507 2019-02-26
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT01185509 2019-01-23
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03358004 2018-10-05
VICTOR3
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT02919462 2018-01-16
HighTySy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT00041470 2017-07-17
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
University of Washington
Phase 1/2 Terminated
NCT00194792 2017-07-11
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Phase 2 Terminated
NCT00088985 2017-06-20
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00455572 2017-05-15
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT00176488 2017-03-23
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT02213744 2017-01-06
HERMIONE
Merrimack Pharmaceuticals
Phase 2/3 Terminated
NCT00597116 2016-10-10
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Phase 2 Terminated
NCT00920153 2016-09-16
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation
Phase 3 Terminated
NCT00345059 2016-01-14
DISTAL-2
National Cancer Institute, Naples
Phase 3 Terminated
NCT00754702 2015-09-28
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
University Hospital of Crete
Phase 2 Terminated
NCT00391586 2015-08-17
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01161368 2015-08-13
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
Central European Cooperative Oncology Group
Phase 2 Terminated
NCT00694200 2015-05-29
Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01038037 2014-12-04
Lung-TRIO
Vejle Hospital
Phase 2 Terminated
NCT01238029 2014-11-21
CELAVIE
Sponsor GmbH
Phase 1 Terminated
NCT00545948 2014-07-21
TOP0703
Duke University
Phase 2 Terminated
NCT00709618 2014-07-14
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
GlaxoSmithKline
Phase 2 Terminated
NCT01060514 2013-10-30
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Northwestern University
Phase 1 Terminated
NCT00049660 2012-07-18
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Terminated
NCT00004093 2012-06-06
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Northwestern University
Phase 1/2 Terminated
NCT00042315 2012-05-23
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
QLT Inc.
Phase 3 Terminated
NCT00453635 2012-03-13
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01254136 2012-01-25
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
Incyte Corporation
Phase 1/2 Terminated
NCT00801151 2010-05-20
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
Institut Claudius Regaud
Phase 1 Terminated
NCT00403988 2008-11-04
Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma
American University of Beirut Medical Center
Phase 2 Terminated